Daisy Ridley, PCOS, and What a Celebrity Pays vs. What You Actually Pay

What Daisy Ridley Has Said About PCOS and Endometriosis

Daisy Ridley, best known for playing Rey in the Star Wars sequel trilogy, has spoken candidly in multiple interviews about being diagnosed with endometriosis and PCOS during her teenage years. She described years of painful periods, acne, and frustration before getting answers, a timeline that mirrors the experience of millions of women.

That candor matters clinically. Endometriosis carries an average diagnostic delay of 7 to 10 years, and PCOS is missed or misdiagnosed in a substantial proportion of women before they ever see a specialist. When a public figure names her diagnoses by their medical terms, searches spike and women book appointments. That is a measurable public-health effect.

Why These Two Conditions Frequently Co-Occur

PCOS and endometriosis are not the same disease, but they share the same patient. Research published in Human Reproduction found that women with endometriosis had a significantly higher prevalence of PCOS than the general population, though the biological mechanism linking them is still being worked out. Both conditions are driven in part by hormonal dysregulation, chronic low-grade inflammation, and, in many cases, insulin resistance.

For a woman trying to make sense of her own symptoms, the practical implication is this: if you have one diagnosis, ask your clinician whether the other should be ruled out.

The Symptom Picture Daisy Ridley Described

Ridley's reported symptoms, painful periods, cystic acne, and a long road to diagnosis, map onto the most common clinical presentation of both conditions in adolescence and young adulthood. The Rotterdam criteria, endorsed by the European Society of Human Reproduction and Embryology, require two of three features for a PCOS diagnosis: oligo-ovulation, hyperandrogenism, and polycystic ovarian morphology on ultrasound. Endometriosis, by contrast, can only be confirmed surgically, though clinical diagnosis is increasingly accepted to avoid unnecessary laparoscopy.

What a Celebrity Actually Pays for PCOS and Endometriosis Care

Here is where the gap becomes concrete. A high-profile actor with access to concierge medicine does not experience the healthcare system the way most women do. The cost difference is not modest.

The Concierge-Level Stack

A celebrity-tier PCOS and endometriosis protocol in a major US city typically includes:

• Concierge primary care or direct-pay OB-GYN: $3,000 to $8,000 per year for unlimited same-day access and longer appointments
• Reproductive endocrinologist (cash-pay, no insurance billing): $500 to $900 per consultation, often 2 to 4 visits per year
• Pelvic MRI or high-resolution transvaginal ultrasound: $800 to $2,500 per scan, repeated annually
• Comprehensive hormonal panel (LH, FSH, free and total testosterone, DHEA-S, AMH, fasting insulin, full thyroid panel): $400 to $1,200 cash-pay at a concierge lab
• Dietitian specializing in PCOS and insulin resistance: $150 to $300 per session, 6 to 12 sessions annually
• Prescription medications (branded, without GoodRx or insurance): $200 to $600 per month for oral contraceptives, spironolactone, or metformin ER at retail
• Acupuncture, integrative add-ons, and wellness concierge services: variable, but $2,000 to $5,000 per year is common in this demographic

Add it up and the realistic annual spend sits between $15,000 and $40,000 for comprehensive, high-touch PCOS and endometriosis management. No insurance denials. No referral delays. Same-day imaging. A nutritionist who calls you back.

What a Regular Patient Pays With Insurance

The same clinical protocol, built on the same evidence base, costs dramatically less through standard insurance plus a telehealth platform.

Here is a realistic annual cost breakdown for an insured woman in the United States accessing PCOS care through a combination of her OB-GYN and a telehealth platform:

| Service | Insured Cost Estimate | |---|---| | Annual OB-GYN visit (copay) | $20 to $50 | | Hormonal blood panel (insurance-covered labs) | $0 to $150 | | Transvaginal ultrasound (after deductible) | $50 to $300 | | Combined oral contraceptive (generic, insured) | $0 to $120/year | | Metformin ER 500-2,000 mg/day (generic) | $12 to $48/year | | Spironolactone 25-100 mg/day (generic) | $20 to $80/year | | Telehealth PCOS consult | $75 to $150 per visit | | PCOS-focused dietitian (telehealth, 4 sessions) | $80 to $200 total with insurance |

Total realistic annual spend: $400 to $2,400.

The clinical outcomes data do not show that celebrity-level spending produces meaningfully better results for uncomplicated PCOS. A 2023 Cochrane review of lifestyle interventions for PCOS found that combined diet and exercise produced comparable improvements in metabolic and reproductive outcomes to pharmaceutical interventions alone in women with a BMI above 25, which is evidence a woman can act on at any income level.

The Evidence-Based PCOS Protocol: What the Guidelines Actually Say

Regardless of what a celebrity's doctor charges, the underlying clinical protocol should follow published guidelines. Here is what that looks like in practice.

First-Line Treatment Depends on Your Primary Goal

ACOG Practice Bulletin No. 194 on PCOS and the 2023 international evidence-based PCOS guideline both organize treatment by the woman's primary concern: cycle regulation, androgen excess (acne and hair), fertility, or metabolic health. No single drug covers all four goals equally.

Goal 1: Cycle regulation and contraception

Combined hormonal contraceptives (CHCs), meaning the pill, patch, or ring, are the first-line pharmacological option for women with PCOS who do not want to conceive. They suppress LH, reduce ovarian androgen production, and regulate bleeding. Any low-androgenic progestin formulation is acceptable; there is no evidence that one branded pill outperforms another for PCOS-specific outcomes.

Goal 2: Androgen excess (acne, hirsutism, hair loss)

Spironolactone 25 to 200 mg daily is the most commonly used anti-androgen in the US for PCOS-related androgen excess. It is often combined with a CHC because spironolactone is teratogenic and requires reliable contraception throughout use. Finasteride is used off-label for female pattern hair loss in PCOS but carries a strict contraindication in pregnancy. Eflornithine cream targets facial hirsutism specifically.

Goal 3: Metabolic health and insulin resistance

Metformin ER 500 to 2,000 mg daily is guideline-supported for metabolic PCOS, particularly in women with impaired glucose tolerance, a BMI above 25, or features of insulin resistance. A meta-analysis of 29 randomized controlled trials found metformin reduced fasting insulin and improved menstrual regularity in women with PCOS. GLP-1 receptor agonists such as semaglutide and liraglutide are increasingly used off-label in PCOS with obesity; the 2023 international guideline notes emerging but still limited evidence in this population.

Goal 4: Fertility

The 2023 international PCOS guideline now recommends letrozole as the first-line ovulation induction agent, replacing clomiphene. Letrozole 2.5 to 7.5 mg on cycle days 3 to 7 produces higher live birth rates in women with PCOS. If oral agents fail, gonadotropins or IVF are the next steps.

Diet and Lifestyle: Not Optional, Not Sufficient Alone

A low-glycemic-index diet reduces insulin levels and improves androgen profiles in women with PCOS. The evidence does not support one named diet over another, Mediterranean-style, low-carb, and anti-inflammatory patterns all show benefit in small trials. A 5 to 10% reduction in body weight in women with PCOS who have overweight or obesity restores ovulation in up to 55% of cases. That is a specific, achievable target, not a vague lifestyle instruction.

How PCOS Changes Across Your Life Stage

PCOS is not a static diagnosis. Its presentation and treatment priorities shift substantially depending on where you are in your reproductive life.

Adolescence and Young Adulthood (Teens to Mid-20s)

This is when most women, including Ridley, first notice symptoms. Acne, irregular periods, and weight changes are often attributed to puberty. Diagnosis is harder because polycystic ovarian morphology is common in adolescent ovaries even without PCOS, so the Rotterdam criteria are applied more cautiously in this age group. Combined oral contraceptives manage symptoms while the diagnostic picture clarifies.

Reproductive Years and Trying-to-Conceive

PCOS is the leading cause of anovulatory infertility. It accounts for approximately 80% of anovulatory infertility cases. If you have PCOS and are trying to conceive, letrozole is the starting point. Your clinician should also check for thyroid disease and hyperprolactinemia, which can mimic or worsen PCOS-related cycle disruption.

Pregnancy

Women with PCOS have a higher risk of gestational diabetes, preeclampsia, and preterm birth compared to women without the condition. A large Swedish cohort study found women with PCOS had a 2.8-fold increased risk of gestational diabetes. Metformin is sometimes continued through the first trimester to reduce miscarriage risk, but this is an individualized decision made with your OB-GYN; the evidence is mixed.

Perimenopause

PCOS does not disappear at menopause. Cycles may actually become more regular as LH levels rise naturally with age, creating a diagnostic trap where women think they are recovering. Metabolic risk, including type 2 diabetes and cardiovascular disease, persists and may worsen through perimenopause in women with PCOS. Glucose monitoring and lipid screening should continue. Hormone therapy for menopausal symptoms is not contraindicated in PCOS but should be selected with attention to metabolic profile.

Pregnancy, Lactation, and Contraception: Drug-Specific Safety

This section covers the most commonly prescribed PCOS medications and what you need to know at every reproductive stage.

Combined Hormonal Contraceptives

Safe in women without contraindications (no migraines with aura, no personal history of thromboembolism, non-smoking). Not appropriate during pregnancy. The CDC Medical Eligibility Criteria for Contraceptive Use provides a Category 1 rating (no restriction) for CHCs in women with PCOS. Breastfeeding women are generally advised to avoid combined estrogen-progestin pills in the first 6 weeks postpartum due to theoretical effects on milk supply; progestin-only options are preferred during lactation.

Spironolactone

Contraindicated in pregnancy. Spironolactone is an anti-androgen and has caused feminization of male fetuses in animal studies. Every woman taking spironolactone for PCOS-related androgen excess must use reliable contraception simultaneously. ACOG is explicit on this point in its PCOS practice bulletin. Spironolactone passes into breast milk; breastfeeding while taking it is generally not recommended.

Metformin

The FDA classifies metformin as Pregnancy Category B. Human data suggest it does not increase the risk of congenital anomalies. Some clinicians continue it through the first trimester in women with PCOS at high risk of miscarriage, though the OMG trial and subsequent analyses have not shown a clear benefit in reducing pregnancy loss. Metformin does pass into breast milk in small amounts; the relative infant dose is approximately 0.3%, well below the 10% threshold generally considered acceptable, and it is considered compatible with breastfeeding.

Letrozole (for ovulation induction)

Letrozole is used specifically to achieve pregnancy, not to prevent it. Once a woman is pregnant, it is discontinued immediately. It should not be taken during pregnancy. Outside of a monitored fertility protocol, letrozole requires reliable contraception because it is teratogenic. The PPCOS II trial, published in the New England Journal of Medicine, confirmed letrozole's superiority over clomiphene for live birth rate in PCOS (27.5% vs. 19.1% per woman).

GLP-1 Receptor Agonists (Semaglutide, Liraglutide)

Contraindicated in pregnancy. Women of reproductive age prescribed semaglutide or liraglutide for PCOS-related metabolic dysfunction must use contraception. The FDA label for semaglutide (Ozempic, Wegovy) states the drug should be discontinued at least 2 months before a planned pregnancy. Data in lactation are absent; avoidance is recommended.

Who This Protocol Is Right For, and Who Should Pause

Not every woman with PCOS needs medication. Not every woman presenting like Ridley, young, with acne and irregular periods, has the same underlying driver.

You Are Likely a Good Candidate for This Protocol If:

• You have a confirmed PCOS diagnosis based on Rotterdam criteria, evaluated by a clinician
• You are in your reproductive years and not currently trying to conceive
• You have androgen-driven symptoms (acne along the jawline, chin, and back; hirsutism; scalp hair thinning at the crown)
• You have metabolic features: fasting glucose above 100 mg/dL, triglycerides above 150, or a waist circumference above 35 inches
• Your irregular cycles are causing distress or increasing endometrial cancer risk through unopposed estrogen

You Should Have a Specialist Review First If:

• You are actively trying to conceive (ovulation induction is a distinct protocol requiring monitoring)
• You have a history of adrenal hyperplasia, Cushing's syndrome, or thyroid disease that has not been fully evaluated (these can mimic PCOS)
• You are postpartum and breastfeeding (medication choices change significantly)
• You are in perimenopause and cycles are changing for that reason rather than PCOS activity
• Your symptoms are severe or your imaging suggests an ovarian cyst requiring further evaluation

The Endometriosis Overlap: What It Changes Clinically

Ridley's dual diagnosis is common and clinically significant. Women with both PCOS and endometriosis represent a genuinely complicated hormonal picture.

Endometriosis is an estrogen-dependent condition. Its first-line hormonal management often involves suppressing estrogen, either through continuous progestin, a levonorgestrel-releasing IUD, or, in more severe cases, GnRH agonists. PCOS management, particularly for women using CHCs, also suppresses ovarian estrogen production. These goals overlap conveniently in many cases: a low-androgenic combined pill or continuous progestin can address both conditions simultaneously.

A 2020 study in Fertility and Sterility found that women with confirmed endometriosis and concurrent PCOS features had more severe dysmenorrhea and higher rates of surgical intervention than women with endometriosis alone. If you have both diagnoses, your clinician should build a treatment plan that addresses both explicitly, not just one at a time.

The evidence base for managing the combination is thin. Most endometriosis trials exclude women with concurrent PCOS, and most PCOS trials exclude women with endometriosis. This is the evidence gap named in the guidelines, and it is worth asking your clinician directly: "Is my treatment plan designed for both conditions?"

What Daisy Ridley's Experience Actually Teaches Us

WomanRx asked Elena Vasquez, MD, OB-GYN and member of our editorial board, to reflect on what the Ridley case illustrates clinically: "The most important thing Daisy Ridley did was name her diagnoses publicly and specifically. Women with PCOS and endometriosis spend years being told their pain is normal or their acne is cosmetic. Hearing a public figure say 'this was real and it had a name' is not a small thing. It changes the appointment that a 19-year-old books the following week."

The clinical lesson is separate from the celebrity angle. Whether you have access to a $900-per-hour reproductive endocrinologist or a $75 telehealth visit, the diagnostic criteria are the same. The medications are the same. The evidence base is the same. What differs is the waiting time, the access, and the number of times you are told to come back in six months before anything is done.

PCOS affects an estimated 116 million women worldwide. A substantial proportion remain undiagnosed for years after symptom onset. The cost of delayed diagnosis is not abstract: it includes years of untreated insulin resistance, endometrial hyperplasia risk from anovulation, and fertility complications that might have been preventable.

Closing Clinical Note

If you recognize Ridley's story in your own, the next step is concrete. Request a fasting insulin level, not just a fasting glucose, alongside the standard PCOS labs (free and total testosterone, LH, FSH, DHEA-S, and AMH). A fasting insulin above 15 mIU/L in a woman with irregular cycles and androgen symptoms is enough clinical signal to begin a metabolic intervention, even before a formal PCOS diagnosis is confirmed. The Endocrine Society's 2013 clinical practice guideline on PCOS supports using insulin resistance markers to guide treatment decisions independent of formal diagnostic classification.